Larimar Therapeutics
LRMR
54 hedge funds and large institutions have $167M invested in Larimar Therapeutics in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
125% more call options, than puts
Call options by funds: $27K | Put options by funds: $12K
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
20% more funds holding
Funds holding: 45 → 54 (+9)
17% more capital invested
Capital invested by funds: $143M → $167M (+$24.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12.64% less ownership
Funds ownership: 94.63% → 81.99% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$2.11M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.26M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.2M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$1.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.05M |
| 3 |
Millennium Management
New York
|
-$2.53M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.98M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$150K |
LRMR Hedge Fund Activity: Q3 2021 in Review
54 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2021, worth a combined $167M — up 17% from $143M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LRMR positions and 4 closed out — a net gain of 9 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $2.11M. The largest seller was Vivo Capital, cutting an estimated $4.8M.
- 54 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2021, up from 45 in Q2 2021.
- Funds reported $167M of Larimar Therapeutics stock for Q3 2021, up 17% quarter-over-quarter.
- 13 funds opened new Larimar Therapeutics positions in Q3 2021 and 4 closed out, a net change of +9 holders.
- The largest Larimar Therapeutics buyer in Q3 2021 was Fred Alger Management, an estimated $2.11M added.
- The largest Larimar Therapeutics seller in Q3 2021 was Vivo Capital, an estimated $4.8M sold.
Based on aggregated 13F filings for Q3 2021.